|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tran L, Xiao JF, Agarwal N, Duex JE and
Theodorescu D: Advances in bladder cancer biology and therapy. Nat
Rev Cancer. 21:104–121. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lenis AT, Lec PM and Chamie K: Bladder
cancer. JAMA. 324:20062020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larsen ES, Joensen UN, Poulsen AM, Goletti
D and Johansen IS: Bacillus Calmette-Guérin immunotherapy for
bladder cancer: A review of immunological aspects, clinical effects
and BCG infections. APMIS. 128:92–103. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao J, Zhou L, Pan Y and Chen L: A
systematic review and meta-analysis of radical cystectomy in the
treatment of muscular invasive bladder cancer (MIBC). Transl Androl
Urol. 10:3476–3485. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo CC and Czerniak B: Molecular taxonomy
and immune checkpoint therapy in bladder cancer. Surg Pathol Clin.
15:681–694. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng Z and Song Y: Synaptopodin-2: A
potential tumor suppressor. Cancer Cell Int. 23:1582023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leinweber BD, Fredricksen RS, Hoffman DR
and Chalovich JM: Fesselin: A novel synaptopodin-like actin binding
protein from muscle tissue. J Muscle Res Cell Motil. 20:539–545.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faul C, Dhume A, Schecter AD and Mundel P:
Protein kinase A, Ca2+/calmodulin-dependent kinase II, and
calcineurin regulate the intracellular trafficking of myopodin
between the Z-disc and the nucleus of cardiac myocytes. Mol Cell
Biol. 27:8215–8227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Ganck A, De Corte V, Bruyneel E, Bracke
M, Vandekerckhove J and Gettemans J: Down-regulation of myopodin
expression reduces invasion and motility of PC-3 prostate cancer
cells. Int J Oncol. 34:1403–1409. 2009.PubMed/NCBI
|
|
11
|
Linnemann A, Vakeel P, Bezerra E, Orfanos
Z, Djinović-Carugo K, van der Ven PF, Kirfel G and Fürst DO:
Myopodin is an F-actin bundling protein with multiple independent
actin-binding regions. J Muscle Res Cell Motil. 34:61–69. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kai F, Fawcett JP and Duncan R:
Synaptopodin-2 induces assembly of peripheral actin bundles and
immature focal adhesions to promote lamellipodia formation and
prostate cancer cell migration. Oncotarget. 6:11162–11174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Ye L, Li Q, Wu X, Wang B, Ouyang Y,
Yuan Z, Li J and Lin C: Synaptopodin-2 suppresses metastasis of
triple-negative breast cancer via inhibition of YAP/TAZ activity. J
Pathol. 244:71–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roperto S: Role of BAG3 in bovine
Deltapapillomavirus-mediated autophagy. J Cell Biochem. 123:59–64.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Faul C, Hüttelmaier S, Oh J, Hachet V,
Singer RH and Mundel P: Promotion of importin alpha-mediated
nuclear import by the phosphorylation-dependent binding of cargo
protein to 14-3-3. J Cell Biol. 169:415–424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z,
Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A
universal enrichment tool for interpreting omics data. Innovation
(Camb). 2:1001412021.PubMed/NCBI
|
|
19
|
Geeleher P, Cox N and Huang RS:
pRRophetic: An R package for prediction of clinical
chemotherapeutic response from tumor gene expression levels. PLoS
One. 9:e1074682014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aran D, Hu Z and Butte AJ: xCell:
Digitally portraying the tissue cellular heterogeneity landscape.
Genome Biol. 18:2202017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EI III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Ju L, Wang G, Qian K, Jin W, Li M,
Yu J, Shi Y, Wang Y, Zhang Y, et al: DNA polymerase POLD1 promotes
proliferation and metastasis of bladder cancer by stabilizing MYC.
Nat Commun. 14:24212023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan TZ, Rouanne M, Tan KT, Huang RY and
Thiery JP: Molecular subtypes of urothelial bladder cancer: Results
from a meta-cohort analysis of 2411 tumors. Eur Urol. 75:423–432.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu X, Lv D, Cai C, Zhao Z, Wang M, Chen W
and Liu Y: A TP53-associated immune prognostic signature for the
prediction of overall survival and therapeutic responses in
muscle-invasive bladder cancer. Front Immunol. 11:5906182020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang S, Hua X, Kuang M, Zhu J, Mu H, Tian
Z, Zheng X and Xie Q: miR-190 promotes malignant transformation and
progression of human urothelial cells through CDKN1B/p27
inhibition. Cancer Cell Int. 21:2412021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koch J, Schober SJ, Hindupur SV, Schöning
C, Klein FG, Mantwill K, Ehrenfeld M, Schillinger U, Hohnecker T,
Qi P, et al: Targeting the Retinoblastoma/E2F repressive complex by
CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic
adenovirus. Nat Commun. 13:46892022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Z, Chen X, Xie R, Huang M, Dong W,
Han J, Zhang J, Zhou Q, Li H, Huang J and Lin T: DANCR promotes
metastasis and proliferation in bladder cancer cells by enhancing
IL-11-STAT3 signaling and CCND1 expression. Mol Ther. 27:326–341.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z, Yu Y, Li P, Wang M, Jiao W, Liang
Y and Niu H: Identification and validation of an immune signature
associated with EMT and metabolic reprogramming for predicting
prognosis and drug response in bladder cancer. Front Immunol.
13:9546162022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alzahrani AS: PI3K/Akt/mTOR inhibitors in
cancer: At the bench and bedside. Semin Cancer Biol. 59:125–132.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash
A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, et al: Phase
II trial of AKT inhibitor MK-2206 in patients with advanced breast
cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN
loss/PTEN mutation. Breast Cancer Res. 21:782019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu W, Zhang Y, Ning J, Li M, Tang Y, Li L,
Cheng F and Yu W: Anti-tumor effect of AZD8055 against bladder
cancer and bladder cancer-associated macrophages. Heliyon.
9:e142722023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Camidge DR, Otterson GA, Clark JW,
Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy
DA, Conte U, et al: Crizotinib in patients with MET-amplified
NSCLC. J Thorac Oncol. 16:1017–1029. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zou Z, Chen J, Yang J and Bai X: Targeted
inhibition of Rictor/mTORC2 in cancer treatment: A new era after
rapamycin. Curr Cancer Drug Targets. 16:288–304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Wu S, Peng Y, Zhao Y, Dong Y, Ran
F, Geng H, Zhang K, Li J, Huang S and Wang Z: Constructing a cancer
stem cell related prognostic model for predicting immune landscape
and drug sensitivity in colorectal cancer. Front Pharmacol.
14:12000172023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun Y, Chen Y, Zhuang W, Fang S, Chen Q,
Lian M, Lv C, Weng J, Wei R, Lin Y, et al: Gastric cancer
peritoneal metastasis related signature predicts prognosis and
sensitivity to immunotherapy in gastric cancer. J Cell Mol Med. Aug
21–2023.(Epub ahead of print). View Article : Google Scholar
|
|
38
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bagchi S, Yuan R and Engleman EG: Immune
checkpoint inhibitors for the treatment of cancer: Clinical impact
and mechanisms of response and resistance. Annu Rev Pathol.
16:223–249. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gan L, Camarena V, Mustafi S and Wang G:
Vitamin C inhibits triple-negative breast cancer metastasis by
affecting the expression of YAP1 and synaptopodin 2. Nutrients.
11:29972019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
OuYang C, Xie Y, Fu Q and Xu G: SYNPO2
suppresses hypoxia-induced proliferation and migration of
colorectal cancer cells by regulating YAP-KLF5 axis. Tissue Cell.
73:1015982021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang SL, Yang CC, Lai HY, Tsai HH, Yeh
CF, Lee SW, Kuo YH, Kang NW, Wu WB and Chen TJ: SYNPO2 upregulation
is an unfavorable prognostic factor for nasopharyngeal carcinoma
patients. Medicine (Baltimore). 102:e344262023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang
X, Liu C, Xue N, Hong H, Xie J, et al: TEAD4 functions as a
prognostic biomarker and triggers EMT via PI3K/AKT pathway in
bladder cancer. J Exp Clin Canc Res. 41:1752022. View Article : Google Scholar
|
|
44
|
Wang J, Shen C, Zhang J, Zhang Y, Liang Z,
Niu H, Wang Y and Yang X: TEAD4 is an immune regulating-related
prognostic biomarker for bladder cancer and possesses
generalization value in pan-cancer. DNA Cell Biol. 40:798–810.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li MO, Wolf N, Raulet DH, Akkari L, Pittet
MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S and
Bhardwaj N: Innate immune cells in the tumor microenvironment.
Cancer Cell. 39:725–729. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang Z, Zhang B, Li D, Lv M, Huang C, Shen
GX and Huang B: Mast cells mobilize myeloid-derived suppressor
cells and Treg cells in tumor microenvironment via IL-17 pathway in
murine hepatocarcinoma model. PLoS One. 5:e89222010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aponte-López A and Muñoz-Cruz S: Mast
cells in the tumor microenvironment. Adv Exp Med Biol.
1273:159–173. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Komi DEA and Redegeld FA: Role of mast
cells in shaping the tumor microenvironment. Clin Rev Allerg Immu.
58:313–325. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dalton DK and Noelle RJ: The roles of mast
cells in anticancer immunity. Cancer Immunol Immunother.
61:1511–1520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Elieh Ali Komi D and Grauwet K: Role of
mast cells in regulation of T cell responses in experimental and
clinical settings. Clin Rev Allergy Immunol. 54:432–445. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim JH, Kang YJ, Kim DS, Lee CH, Jeon YS,
Lee NK and Oh MH: The relationship between mast cell density and
tumour grade in transitional cell carcinoma of the bladder. J Int
Med Res. 39:1675–1681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Visciano C, Liotti F, Prevete N, Cali' G,
Franco R, Collina F, de Paulis A, Marone G, Santoro M and Melillo
RM: Mast cells induce epithelial-to-mesenchymal transition and stem
cell features in human thyroid cancer cells through an
IL-8-Akt-Slug pathway. Oncogene. 34:5175–5186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Morad G, Helmink BA, Sharma P and Wargo
JA: Hallmarks of response, resistance, and toxicity to immune
checkpoint blockade. Cell. 185:5762022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jiang LR, Zhang N, Chen ST, He J, Liu YH,
Han YQ, Shi XQ, Yang JJ, Mu DY, Fu GH and Gao F: PD-1-positive
tumor-associated macrophages define poor clinical outcomes in
patients with muscle invasive bladder cancer through potential
CD68/PD-1 complex interactions. Front Oncol. 11:6799282021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Somasundaram R, Connelly T, Choi R, Choi
H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M,
et al: Tumor-infiltrating mast cells are associated with resistance
to anti-PD-1 therapy. Nat Commun. 12:3462021. View Article : Google Scholar : PubMed/NCBI
|
